{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:44:30Z","timestamp":1777934670951,"version":"3.51.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat various types of cancers. Although widely used, it has consistently been attributed to cardiotoxicities after administration. The purpose of this study was to assess the parameters and predictors of cardiotoxicities associated with various 5-FU-based chemotherapeutic protocols in patients with GI\/colorectal cancer, as well as the correlation of these cardiotoxic events with age, sex, cumulative dose, and risk factors such as obesity, hypertension, and family history of cardiac diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective study consisting of 396 patients of both sexes was conducted in the oncology ward of Nishtar Hospital in Multan, Pakistan. Patients were grouped according to the therapeutic protocol they received (5-FU monotherapy or in combination, with different dosing regimens). Electrocardiography and serum troponin levels were used to assess 5-FU-induced cardiotoxicity. In cases where cardiotoxicity was detected, 5-FU treatment was interrupted; nitroglycerin, nitrates, and calcium channel blockers were administered; and cardiac monitoring was initiated. 5-FU was discontinued in all cases of acute myocardial infarction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 396 patients, 28.5% reported different cardiotoxic symptoms after receiving various 5-FU-containing protocols. 35% had anginal pain, 13% suffered a myocardial infarction, 11% developed hypertension, and 10% presented heart failure. Patients receiving 5-FU combination therapy showed cardiotoxic events that were significantly different from those on 5-FU monotherapy. Based on the ECG results, only the QTc-d interval increased significantly (p\u2009&lt;\u20090.001) after therapy. 68% of the patients had troponin levels &gt;\u20092 ng\/mL at the end of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pre-existing cardiac diseases, treatment duration, smoking, and obesity were found to be influential components in the development of cardiotoxicity, and patients with cancer should be closely monitored during 5-FU chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241275948","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T05:21:58Z","timestamp":1727932918000},"page":"1037-1045","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigation of 5-fluorouracil cardiotoxicity in combinational therapy: Influence of risk factors and demographics in a Pakistani population"],"prefix":"10.1177","volume":"31","author":[{"given":"Hina","family":"Raza","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariyam","family":"Javaid","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wajiha","family":"Rehman","sequence":"additional","affiliation":[{"name":"Jazan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana","family":"Rafiq","sequence":"additional","affiliation":[{"name":"King Edward Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zermina","family":"Rashid","sequence":"additional","affiliation":[{"name":"The Women University Multan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahat","family":"Shamim","sequence":"additional","affiliation":[{"name":"Punjab University College of Pharmacy, University of the Punjab, Punjab, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdolelah","family":"Jaradat","sequence":"additional","affiliation":[{"name":"Isra University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2180-0480","authenticated-orcid":false,"given":"Mohamed Deifallah","family":"Yousif","sequence":"additional","affiliation":[{"name":"UCL School of Pharmacy, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05508.x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy453"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918780140"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.2012.0084"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyi071"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.11.1795"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-007-0250-9"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/030089168206800609"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-15-47"},{"key":"e_1_3_3_11_2","volume-title":"CANCER","author":"Robben NC","year":"1993","unstructured":"Robben NC, Pippas AW, Moore JO. The Syndrome of 5-Fluorouracil Cardiotoxicity. CANCER. 1993; 71 (2): 493\u2013509."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3283165f27"},{"key":"e_1_3_3_13_2","first-page":"3028","article-title":"In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle","volume":"53","author":"Mosseri M","year":"1993","unstructured":"Mosseri M, Fingert HJ, Varticovski L, et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993; 53: 3028\u20133033.","journal-title":"Cancer Res"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.15420\/icr.2019.12"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-019-0048-3"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1997.tb03748.x"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2012.09.003"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38127-2"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2004.00556.x"},{"key":"e_1_3_3_20_2","first-page":"205","article-title":"5-fluorouracil Cardiotoxicity is a rare, dose and schedule-dependent adverse event: a prospective study","volume":"10","author":"Tsavaris N","year":"2005","unstructured":"Tsavaris N, Kosmas C, Vadiaka M, et al. 5-fluorouracil Cardiotoxicity is a rare, dose and schedule-dependent adverse event: a prospective study. Journal of BUON 2005; 10: 205\u2013211.","journal-title":"Journal of BUON"},{"key":"e_1_3_3_21_2","first-page":"2085","article-title":"Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2\u2019- tetrahydrofuryl)-5-fluorouracil","volume":"4","author":"Ho DH","year":"1998","unstructured":"Ho DH, Pazdur R, Covington W, et al. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2\u2019- tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 1998; 4: 2085\u20132088.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.156"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00543978"},{"key":"e_1_3_3_24_2","volume-title":"Metabolites of 5-Fluorouracil, \u03b1-Fluoro-\u03b2-Alanine and Fluoroacetic Acid, Directly Injure Myelinated Fibers in Tissue Culture","author":"Akiba T","year":"1997","unstructured":"Akiba T. Metabolites of 5-Fluorouracil, \u03b1-Fluoro-\u03b2-Alanine and Fluoroacetic Acid, Directly Injure Myelinated Fibers in Tissue Culture. National Diet Library. Tokyo Medical and Dental University, 1997. doi:https:\/\/doi.org\/10.11501\/3129556"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-003-0319-7"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2015.12.023"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-0719-1"},{"key":"e_1_3_3_28_2","first-page":"1783","article-title":"Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients\u2019 heart?","volume":"7","author":"Fontanella C","year":"2014","unstructured":"Fontanella C, Aita M, Cinausero M, et al. Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients\u2019 heart? Onco Targets Ther 2014; 7: 1783\u20131791.","journal-title":"Onco Targets Ther"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-198710000-00004"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2009.n.009"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00868.2010"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.12.005"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311170"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.306883"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.111.964627"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241275948","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241275948","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241275948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:30:12Z","timestamp":1777689012000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241275948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/10781552241275948"],"URL":"https:\/\/doi.org\/10.1177\/10781552241275948","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]}}}